Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Novavax, Inc.    NVAX

NOVAVAX, INC.

(NVAX)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/12/2019 08/13/2019 08/14/2019 08/15/2019 08/16/2019 Date
4.02(c) 4.3(c) 6.04(c) 6.62(c) 7.84(c) Last
382 107 620 152 6 813 618 3 309 921 5 600 784 Volume
-3.13% +6.97% +40.47% +9.60% +18.43% Change
More quotes
Financials (USD)
Sales 2019 11,2 M
EBIT 2019 -122 M
Net income 2019 -134 M
Debt 2019 291 M
Yield 2019 -
Sales 2020 2,60 M
EBIT 2020 -124 M
Net income 2020 -147 M
Debt 2020 291 M
Yield 2020 -
P/E ratio 2019 -1,43x
P/E ratio 2020 -1,81x
EV / Sales2019 42,9x
EV / Sales2020 184x
Capitalization 188 M
More Financials
Company
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine... 
More about the company
Surperformance© ratings of Novavax, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVAVAX, INC.
08/13NOVAVAX : New Data from Novavax Phase 3 Prepare Trial of ResVax Presented at 201..
AQ
08/12Influenza Vaccines Market is Expected to Surpass USD 6 billion by 2025 | Key ..
AQ
08/12New Data from Novavax Phase 3 Prepare™ Trial of ResVax™ Presented..
GL
08/08NOVAVAX INC : Results of Operations and Financial Condition, Financial Statement..
AQ
08/08NOVAVAX : Scientific Leadership to Present New RSV Maternal Immunization Program..
AQ
08/07NOVAVAX : 2Q Earnings Snapshot
AQ
08/07NOVAVAX : Management's Discussion and Analysis of Financial Condition and Result..
AQ
08/07Novavax Reports Second Quarter 2019 Financial Results
GL
08/05NOVAVAX : Reaches Agreement with the FDA on Pivotal Phase 3 Trial Design for Nan..
AQ
08/01NOVAVAX INC : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
08/15European Medicines Agency Reviews Arthritis Treatment by Gilead, Galapagos
DJ
08/12REGENERON PHARMACEUTICALS : Two Experimental Ebola Drugs Reduce Mortality Rate
DJ
08/08Sarepta says adverse event report for DMD gene therapy erroneously submitted
RE
08/08AGENUS : FDA Accepts AGEN2373 IND, Triggering $7.5 Million Milestone
DJ
08/07NOVARTIS : Medicare Moves to Cover Costly Cell Therapies
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 19,42  $
Last Close Price 7,84  $
Spread / Highest target 442%
Spread / Average Target 148%
Spread / Lowest Target -23,5%
EPS Revisions
Managers
NameTitle
Stanley C. Erck President, Chief Executive Officer & Director
James F. Young Chairman
Timothy Jon Hahn Senior VP-Global Manufacturing Operations
John J. Trizzino CFO, Treasurer, Chief Business Officer & Senior VP
Louis F. Fries Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVAVAX, INC.-78.70%158
IQVIA HOLDINGS INC33.61%29 805
LONZA GROUP34.43%25 750
INCYTE CORPORATION30.71%17 337
CELLTRION, INC.--.--%16 155
EXACT SCIENCES CORPORATION87.35%15 308